Company intelligence / Profile preview
Avista Therapeutics
Pittsburgh, Pennsylvania, United Statesavistatx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
As of May 2025, Avista Therapeutics remains a preclinical-stage company. It has not yet reported clinical trial results but has announced rapid translation of new gene therapies to the clinic using its proprietary scAAVengr platform for next-generation AAV vector development targeting inherited and rare retinal diseases[1][3].
- Therapeutic areas
- Ophthalmology
- Modalities
- AAV gene therapy (adeno-associated virus vectors)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Roche – partnership to develop next-generation AAV gene therapy vectors for ocular diseases[1]
Beyond the preview
Go deeper on Avista Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avista Therapeutics.